Related references
Note: Only part of the references are listed.Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia
David J. Kuter
ANNUAL REVIEW OF MEDICINE (2009)
Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk
Anna Podolanczuk et al.
BLOOD (2009)
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
James B. Bussel et al.
BLOOD (2009)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero et al.
BLOOD (2009)
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
James B. Bussel et al.
LANCET (2009)
Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura
Robert McMillan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Rituximab efficacy and. safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:: results of a prospective multicenter phase 2 study
Bertrand Godeau et al.
BLOOD (2008)
Emerging drugs for idiopathic thrombocytopenic purpura in adults
Xiaofang Li et al.
EXPERT OPINION ON EMERGING DRUGS (2008)
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
Francesco Zaja et al.
HAEMATOLOGICA (2008)
Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal
M. A. Feudjo-Tepie et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura:: a double-blind randomised controlled trial
David J. Kuter et al.
LANCET (2008)
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
Roberto Stasi et al.
BLOOD (2007)
Current options for the treatment of idiopathic thrombocytopenic purpura
Donald M. Arnold et al.
SEMINARS IN HEMATOLOGY (2007)
Multistep pathogenesis of autoimmune disease
Christopher C. Goodnow
CELL (2007)
Progressive multifocal leukoencephalopathy in rheumatic diseases - Evolving clinical and pathologic patterns of disease
Leonard H. Calabrese et al.
ARTHRITIS AND RHEUMATISM (2007)
Infectious complications of monoclonal antibodies used in cancer therapy - A systematic review of the evidence from randomized controlled trials
Petros I. Rafailidis et al.
CANCER (2007)
Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist
Julian M. Jenkins et al.
BLOOD (2007)
An 18-year review of open and laparoscopic splenectomy for idiopathic thrombocytopenic purpura
Sharadh Sampath et al.
AMERICAN JOURNAL OF SURGERY (2007)
Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience
Maria Gabriella Mazzucconi et al.
BLOOD (2007)
Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
Donald M. Arnold et al.
ANNALS OF INTERNAL MEDICINE (2007)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura
Adrian Newland et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis
Petra Roll et al.
ARTHRITIS AND RHEUMATISM (2006)
Mechanisms of disease: Lineage-specific hematopoietic growth factors
K Kaushansky
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the transfusion medicine/hemostasis clinical trials network with a systematic review of rituximab therapy for immune-mediated disorders
JN George et al.
JOURNAL OF CLINICAL APHERESIS (2006)
New benzimidazoles as thrombopoietin receptor agonists
IG Safonov et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis
MJ Leandro et al.
ARTHRITIS AND RHEUMATISM (2006)
Differential roles of microtubule assembly and sliding in proplatelet formation by megakaryocytes
SR Patel et al.
BLOOD (2005)
How I treat idiopathic thrombocytopenic purpura (ITP)
DB Cines et al.
BLOOD (2005)
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010
LD Kaplan et al.
BLOOD (2005)
Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist
CL Erickson-Miller et al.
EXPERIMENTAL HEMATOLOGY (2005)
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
N Cooper et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment
MD Feese et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
AMG531 stimulates megakaryopoiesis in vitro by binding to Mp1
VC Broudy et al.
CYTOKINE (2004)
A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy
RA Du Pasquier et al.
BRAIN (2004)
Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand
B Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H-pylori-associated chronic idiopathic thrombocytopenic purpura
T Takahashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
K Kojouri et al.
BLOOD (2004)
Mouse CD20 expression and function
J Uchida et al.
INTERNATIONAL IMMUNOLOGY (2004)
T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura
B Olsson et al.
NATURE MEDICINE (2003)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy
BF Sabath et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab
J Golay et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Recombinant human thrombopoietin: basic biology and evaluation of clinical studies
DJ Kuter et al.
BLOOD (2002)
Overview of 321 patients with idiopathic thrombocytopenic purpura -: Retrospective analysis of the clinical features and response to therapy
GE Pamuk et al.
ANNALS OF HEMATOLOGY (2002)
Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura
S Nomura et al.
BLOOD (2002)
Crystallization of the functional domain of human thrombopoietin using an antigen-binding fragment derived from neutralizing monoclonal antibody
R Kuroki et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2002)
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor
RL Basser et al.
BLOOD (2002)
Medical progress: Immune thrombocytopenic purpura.
DB Cines et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo
S Scheding et al.
TRANSFUSION (2002)
Thrombocytopenia caused by the development of antibodies to thrombopoietin
JZ Li et al.
BLOOD (2001)
Risk of infection and death among post-splenectomy patients
N Bisharat et al.
JOURNAL OF INFECTION (2001)
Morbidity and mortality in adults with idiopathic thrombocytopenic purpura
JEA Portielje et al.
BLOOD (2001)
The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts
YC Cohen et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer
S Vadhan-Raj et al.
ANNALS OF INTERNAL MEDICINE (2000)
Share Paper
